LB Pharmaceuticals Inc · NASDAQ:LBRX

LB Pharmaceuticals — Investor Presentation (January 2025)

20 slides from LB Pharmaceuticals's investor presentation, January 2025

  1. Slide 1: Developing Novel Therapies for Neuropsychiatric Disorders

    LB PHARMACEUTICALS LB Pharmaceuticals Inc Developing Novel Therapies for Neuropsychiatric Disorders January 2025 PROPRIETARY - NOT FOR DISTRIBUTION 1

  2. Slide 2: Potential to Transform the Treatment of Neuropsychiatric Disorders

    LB PHARMACEUTICALS Potential to Transform the Treatment of Neuropsychiatric Disorders Potential first benzamide antipsychotic (AP) in the U.S.; Strong safety and successful Phase 2 results; Phase 3 initiation in 2025 and efficacy in schizophrenia data expected in 2027 Opportunity to pursue Potential

  3. Slide 3: World-class Leadership Backed by Premier KOLs and Investors

    LB PHARMACEUTICALS World-class Leadership Backed by Premier KOLs and Investors Board of Directors Heather Turner Chief Executive Officer/Director Scott Garland Board Chair Former CEO of Carmot Therapeutics, multiple CEO/ COO Rajul Jain, MD Vida Ventures and biotech leadership roles Rebecca Luse Deep

  4. Slide 4: Significant Unmet Need Persists in Schizophrenia

    LB PHARMACEUTICALS Significant Unmet Need Persists in Schizophrenia Limited Efficacy for The Burden of Side Effects and Too Many Patients Negative Symptoms Compliance Issues • ~50% of patients fail to • Up to 60% of patients2 • Sedation, extrapyramidal respond to existing symptoms (EPS), GI therapie

  5. Slide 5: Widespread AP Switching Highlights Therapeutic Shortfalls

    LB PHARMACEUTICALS Widespread AP Switching Highlights Therapeutic Shortfalls = Current Distribution of Schizophrenia Patients Across AP Treatment1 67% of treated 40% schizophrenia patients 35% 67% of Patients switch APs due to 30% limited efficacy or % Patients 25% 20% tolerability1 15% 33% 31% 22%

  6. Slide 6: New Chemical Class for Treatment of Schizophrenia in U.S.

    LB PHARMACEUTICALS New Chemical Class for Treatment of Schizophrenia in U.S. Amisulpride profile enhanced Intellectual Property by adding a methyl group Amisulpride • Composition of matter until at least 20401 • Patents: 7 U.S. issued, LB-102 11 foreign issued; 2 U.S. pending, 24 foreign pending 1 I

  7. Slide 7: Phase 2 NOVA1 Clinical Trial Design

    LB PHARMACEUTICALS Phase 2 NOVA1 Clinical Trial Design 4-week, in-patient, double-blinded, placebo-controlled, oral once daily dose in acute schizophrenia patients • 359 patients at 19 U.S. clinical trial sites • Initiated in November 2023 • 50 mg, 75 mg, 100 mg1 and placebo (randomized: 3:3:1:3) •

  8. Slide 8: Baseline Demographics Consistent with Other Schizophrenia Trials

    LB PHARMACEUTICALS Baseline Demographics Consistent with Other Schizophrenia Trials 50 mg 75 mg 100 mg Placebo Overall n 107 108 36 108 359 Age at IC (SD) 39 (9.6) 39.2 (9.2) 39.1 (9.2) 39.1 (9.2) 39.1 (9.3) Male n (%) 87 (81) 90 (83) 28 (78) 85 (79) 290 (81) Female n (%) 20 (19) 18 (17) 8 (22) 23 (

  9. Slide 9: Statistically Superior Efficacy to Placebo at All Three Doses

    LB PHARMACEUTICALS Statistically Superior Efficacy to Placebo at All Three Doses Effect Size vs. Placebo Dose Effect Size LS Means in PANSS Total Score Change from Baseline 50 mg vs. PBO 0.61 75 mg vs. PBO 0.41 Treatment Group LB-102 50 mg LB-102 100 mg LB-102 75 mg Placebo 100 mg vs. PBO 0.83 Basel

  10. Slide 10: 100 mg Dose Effect Size Greater than Approved SCZ Drugs

    LB PHARMACEUTICALS 100 mg Dose Effect Size Greater than Approved SCZ Drugs Effect size (Overall Drug change in symptoms) Clozaril/Clozapine1 0.89 Solian/Amisulpride1 0.73 Effect size (Overall change LB-102 Dose Risperdal/Risperidone1 0.55 in symptoms)3 LB-102 (100 mg) 0.83 Invega/Paliperidone1 0.49

  11. Slide 11: PANSS Δ In Line with Recently Approved SCZ Drugs

    LB PHARMACEUTICALS PANSS ∆ In Line with Recently Approved SCZ Drugs PROPRIETARY - NOT FOR DISTRIBUTION 11

  12. Slide 12: Adverse Events Reported in ≥5% of Patients

    LB PHARMACEUTICALS Adverse Events Reported in ≥5% of Patients Number of subjects (% of treatment group) Preferred Term 50 mg (N=107) 75 mg (N=108) 100 mg (N=36) Placebo (N=108) Insomnia 27 (25.2%) 23 (21.3%) 14 (38.9%) 24 (22.2%) Headache 12 (11.2%) 9 (8.3%) 2 (5.6%) 10 (9.3%) Anxiety 10 (9.3%) 9 (8

  13. Slide 13: Adverse Events of Interest

    LB PHARMACEUTICALS Adverse Events of Interest EPS Sedation Number of subjects (% of treatment group) Number of subjects (% of treatment group) 50 mg 75 mg 100 mg Placebo 50 mg 75 mg 100 mg Placebo Preferred Term Preferred Term (N=107) (N=108) (N=36) (N=108) (N=107) (N=108) (N=36) (N=108) Dystonia 0

  14. Slide 14: AE Related Trial Discontinuations and SAEs

    LB PHARMACEUTICALS AE Related Trial Discontinuations and SAEs Discontinuations Due to AEs by Dose Serious Adverse Events Dose % Reported AE Dose % Reported AE Suicidal ideation*, Exacerbation of Suicidal ideation* 50 mg 1.9% 50 mg <1% psychosis+ COVID-19o, Dystonia*, Increased amylase 75 mg <1% Acut

  15. Slide 15: Potential to Compete in Schizophrenia and Other Markets

    LB PHARMACEUTICALS Potential to Compete in Schizophrenia and Other Markets • Statistically superior efficacy to placebo at all doses • Marked effect sizes were observed at all doses (50 mg = 0.61; 75 mg = 0.41; 100 mg = 0.83) • Clinically meaningful PANSS reduction at all three doses • Efficacy comp

  16. Slide 16: Potential to Address ~12M Patients in Additional Indications

    LB PHARMACEUTICALS Potential to Address ~12M Patients in Additional Indications Predominantly negative Alzheimer’s Disease (AD) Bipolar depression (BPD): symptoms of SCZ: psychosis and agitation: ~1 million U.S. patients ~7 million U.S. patients ~4 million U.S. patients • Amisulpride outperformed •

  17. Slide 17: Potential to be Formulated as an LAI

    LB PHARMACEUTICALS Potential to be Formulated as an LAI LAI’s are key to reduce the risk of relapse LB-102 LAI Consistent drug exposure • Opportunity for novel IP • Global market expansion Improved compliance • ~$6 billion market opportunity2 Reduced hospitalization and improved functional outcomes

  18. Slide 18: Multiple Expected Inflection Points Within Next 24 Months

    LB PHARMACEUTICALS Multiple Expected Inflection Points Within Next 24 Months Preclinical Phase 1 Phase 2 Phase 3 Anticipated milestones Acute Phase 3 • Initiation Q4 2025 Schizophrenia LB-102 (Oral) Expansion Phase 2 • Initiation Q1 2026 Indication(s) Elderly Population Phase 1 safety trial • Initia

  19. Slide 19: Potential to Transform the Treatment of Neuropsychiatric Disorders

    LB PHARMACEUTICALS Potential to Transform the Treatment of Neuropsychiatric Disorders Potential first benzamide antipsychotic (AP) in the U.S.; Strong safety and successful Phase 2 results; Phase 3 initiation in 2025 and efficacy in schizophrenia data expected in 2027 Opportunity to pursue Potential

  20. Slide 20: Thank you!

    LB PHARMACEUTICALS LB Pharmaceuticals Inc Thank you! PROPRIETARY - NOT FOR DISTRIBUTION 20

LB Pharmaceuticals — Investor Presentation (January 2025) on 6ix